N-PLS-DA METHODOLOGICAL DETAILS
The transcriptome data set was represented as a multiway data set (subjectprobe set [gene]time). In the N-PLS-DA, the data were transformed in to a series of components (similar to principal component analysis [PCA] (Jackson, 1991; Jolliffe, 2002) ) where the first component encapsulates the most variation in the total data set that correlates with controlled human malaria infection (CHMI) outcome, and the subsequent components encapsulate progressively less variation. Together, these factors describe variations in the data set which were encapsulated in predictive mathematical models. Hence the kinetics of the changes induced by the vaccination were captured explicitly in each of the mathematical models.
Each mathematical model was generated through the iterative selection of probe sets and the selection of the minimal number of components required from the transformed data set to achieve optimal model performance. Model performance was evaluated by a double cross validation (DCV) approach. DCV resulted in 10 collections (ensembles) of 10 models of correlation, yielding a total of 100 individual models, with performance statistics. The difference in model performance was identified using the DQ 2 statistic. This statistic is based on a least-squares method for analyzing the difference between prediction and CHMI outcome (Westerhuis et al., 2008) and was more discriminatory than using the fraction of correctly classified outcomes. The consideration of two or three components was typically sufficient for optimal prediction performance. Each model typically consisted of data from 2-40 probe sets and optimal performance was typically observed after several rounds of probe set selection. Predictive performance was validated using label permutation. The worst, average and best model performance measures in a given ensemble of models were always higher than the most frequent performance measure generated by label ) for improved discrimination in PLSDA models. Metabolomics 4, 293-296.
SUPPLEMENTARY TABLE 1
Genes/probe sets selected by the data-driven modeling
Gene
Probe set ID Frequency of use in models Cluster For genes with more than one probe set, the data from b the probe set that was most frequently represented in the models were considered as the representative data for that gene in the manuscript.
HLA-DMB
203932_at 1 B HSP90B1 200598_s_at 2 B ICAM2 213620_s_at 1 D IDH3G 202471_s_at 6 B IL23A 217328_at 4 A IPW 241834_at 1 A IRF7 208436_s_at 1 B KLHL6 1560396_at 1 B LMLN 244881_at 3 A LRPAP1 201186_at 11 D LRRC14 32062_at 1 D LSMEM1 239203_at 2 C LYRM2 227712_at 6 D MRFAP1 226091_s_at 1 C MT1F 217165_x_at 2 B MT2A 212185_x_at 1 B MYBBP1A 219098_at 1 D MYD88 209124_at 32 B NAP1L5 228062_at 1 A NAPRT1 226707_at 1 B NCAPH2 40640_at 13 B NCBP2-AS2 225657_at 9 D NCF1C 214084_x_at 1 B NOB1 223018_at 57 D NSD1 219084_at 2 B NUCKS1 229353_s_at 1 D NUDT14 231914_at 2 D OR2A9P 222290_at 10 A ORC2 204853_at 11 A PDCD4 212593_s_at 1 A PDZK1 205380_at 1 A PLA2G12A 242323_at 2 A PLIN2 209122_at 1 DPMF1 202337_at 2 D PML 211012_s_at 8 B POLE4 1553587_a_at 1 B PTPN6 206687_s_at 1 B PUS7L 229751_s_at 3 A RAD23A 201046_s_at 1 D RAPH1 225189_s_at 1 A RBBP6 227635_at 5 B RHBDF2 219202_at 1 B RIC8A 221647_s_at 2 D RMND5A 212482_at 4 A RNASEH2C 226453_at 2 B RNF31 231635_x_at 58 B RPF2 225866_at 1 D RPL23 200888_s_at 7 C RPS6KA3 203843_at 2 D RRAS 212647_at 3 D SCO2 205241_at 8 B SELPLG 209879_at 1 D SFXN3 217226_s_at 1 D SHARPIN 220973_s_at 5 D SP110 a,b 223980_s_at 3 B SP110 a 209762_x_at 2 B SRSF1 211784_s_at 1 C STK10 40420_at 1 D STUB1 217934_x_at 8 D SWT1 223548_at 1 A TAF1 227205_at 1 A TAF10 200055_at 1 D TAX1BP1 200977_s_at 1 B TBCB a,b 211759_x_at 17 D TBCB a 216194_s_at 1 D TNIP2 48531_at 1 B TRAPPC5 225870_s_at 1 D TRIM26 202702_at 4 B TRIM52 1568594_s_at 1 A TSTA3 36936_at 1 D
SUPPLEMENTARY TABLE 2
References to support the characterization of the immune-related genes selected by the data-driven modeling. Hakem et al., 1991; Girdlestone et al., 1993; Min et al., 1996; Boehm et al., 1997; Girdlestone, 2000; Johnson, 2003; Shen et al., 2009; Othman et al., 2012; Norman et al., 2013; Sleiman et al., 2014) Pan et al., 2005; Tosh et al., 2006; Abhimanyu et al., 2011; Cai et al., 2013; Fox et al., 2014) HLA-B B 2 + (Chamberlain et al., 1991; Hakem et al., 1991; Min et al., 1996; Boehm et al., 1997) HSP90B1 B 2 + + (Randow and Seed, 2001; Yang et al., 2007; Liu et al., 2010; Staron et al., 2010) et al., 2002; Borg et al., 2004; Gismondi et al., 2004; Huang et al., 2005; Krzewski et al., 2006; Serrano-Pertierra et al., 2012; Ham et al., 2013; Catucci et al., 2014; Sarkar et al., 2014; 2015) HLA-C B 1 + a + (Boehm et al., 1997; Boss, 1997; Johnson, 2003; Shen et al., 2009; Othman et al., 2012) HLA Endo, J., Toyama-Sorimachi, N., Taya, C., Kuramochi-Miyagawa, S., Nagata, K., Kuida, K. et al. (2000) . Deficiency of a STE20/PAK family kinase LOK leads to the acceleration of LFA-1 clustering and cell adhesion of activated lymphocytes. Gupta-Rossi, N., Storck, S., Griebel, P.J., Reynaud, C.A., Weill, J.C., and Dahan, A. Tokunaga, F., Nakagawa, T., Nakahara, M., Saeki, Y., Taniguchi, M., Sakata, S. et al. (2011) . SHARPIN is a component of the NF-B-activating linear ubiquitin chain assembly complex. Nature 471, 633-636.
Tosh, K., Campbell, S.J., Fielding, K., Sillah, J., Bah, B., Gustafson, P. et al. (2006 
SUPPLEMENTARY TABLE 3
Genes/probe sets used in the IFN-driven modeling For genes with more than one probe set, the data from the b probe set that was most frequently represented in the models were considered as the representative data for that gene in the manuscript.
c Genes/probe sets that were not selected by the modeling process.
SUPPLEMENTARY FIGURE 2
The evaluation of IFN-pathway gene expression for a potential microarray-batch effect using the validation-transcriptome data set.
Unlike the principal transcriptome data set, the validation transcriptome data set was generated from a single kit of microarrays. The heatmap describes IFN pathway gene expression in protected (PR), non-protected (NP) and non-protected with delayed onset of parasitemia (DL) groups before (prePIII) and 1, 3 and 14 days after the third vaccine injection (1dPIII, 3dPIII and 14dPIII, respectively). Mean RNA expression relative to prePI is described in accordance with the colored scale. Certain genes are represented by more than one probe set. JAK1  IFITM2  IFITM1  IRF7  PTPN2  PTPN2  ISG20  ISG20  IFITM1  IFNGR2  PSMB8  BAK1  GBP1  JAK2  JAK2  EIF2AK2  MX2  OAS2  IFI44  GBP1  STAT1  STAT1  IFIT3  CXCL10  IFI35  OAS3  OAS1  OASL  IFI16  IFIT1  OAS2  IFI16  IFIH1  ISG15  IFI44  OASL  DDX58  CCL8  RTP4  IRF9  OAS1  IFI16  IRF1  TAP1  MX1  MT1G  MT2A  IFITM3  MT1E  BAX  BAX  RELA  SOCS1  SOCS1  IFNGR1  IFNGR1  EIF2AK2  PIAS1  BCL2  PIAS1  PIAS1  BCL2  BCL2   prePIII  1dPIII  3dPIII  14dPIII  prePIII  1dPIII  3dPIII  14dPIII  prePIII  1dPIII  3dPIII 
Gene

SUPPLEMENTARY FIGURE 3
Evaluation of the expression of Clusters A to D probe sets for a potential microarray-batch effect using the validation transcriptome data set.
Unlike the principal transcriptome data set, the validation transcriptome data set was generated from a single kit of microarrays (Vahey et al., 2010) . Mean RNA-expression levels relative to pre-dose 1 (prePI), at pre-dose 3 [prePIII] and 1, 3 and 14 days after dose 3 [1dPIII, 3dPIII, and 14d PIII, respectively])., with respect to protection status of subjects ( 
